Adelaide Research & Scholarship
Statistics
Total Visits
| Views | |
|---|---|
| Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma(legacy) | 106 |
| Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma(legacy) | 68 |
Total Visits per Month
| October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
|---|---|---|---|---|---|---|---|
| Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma | 0 | 6 | 1 | 1 | 1 | 5 | 3 |
File Downloads
| Views |
|---|
Top Country Views
| Views | |
|---|---|
| United States | 66 |
| Australia | 17 |
| China | 10 |
| France | 10 |
| Germany | 8 |
| Netherlands | 8 |
| Vietnam | 8 |
| Argentina | 1 |
| Singapore | 1 |
Top City Views
| Views | |
|---|---|
| Ashburn | 27 |
| Kaleen | 14 |
| Hanoi | 8 |
| Rotterdam | 8 |
| Fairfield | 5 |
| Cambridge | 2 |
| Guangzhou | 2 |
| New York | 2 |
| Ann Arbor | 1 |
| Dearborn | 1 |